Key result
A patient developed severe cardiac dysfunction related to cancer therapeutics, highlighting the need for regular echocardiographic evaluation and sensitive parameters for early detection.
Case Report (n=1)
Highlights the critical role of regular echocardiographic monitoring for early detection of chemotherapy-induced cardiotoxicity before irreversible heart failure occurs.
Answers are grounded in this paper and cite their sources.
Serial echocardiography may detect subclinical CTRCD early; this case leaves open the need for prospective validation before changing practice.
Cardiotoxicity is the most important side effect of cancer therapy resulting in increased patient morbidity and mortality, therefore understanding its occurrence mechanism and a correct and early diagnosis are essential for patients at risk of irreversible heart failure. We present the case of a patient who developed cancer therapeutics-related cardiac dysfunction, emphasizing the importance of regular echocardiographic evaluation for early detection of subclinical cardiac dysfunction and further cardiac monitoring. More sensitive parameters should be used to predict cardiotoxicity because the probability of cardiac function recovery diminishes in time, despite optimal heart failure treatment.
No takes yet. Share an insight, caveat, or question.
Cherata et al. (2015) conducted a case report in Cancer therapeutics-related cardiac dysfunction (n=1). Cancer therapy was evaluated on Cancer therapeutics-related cardiac dysfunction. A patient developed severe cardiac dysfunction related to cancer therapeutics, highlighting the need for regular echocardiographic evaluation and sensitive parameters for early detection.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: